Effects of Androgen Therapy on Prostatic Markers in Hemodialyzed Patients

REFERENCES

• Aguilera A, Teruel JL, García Otero G, Marcén R, Liaño F, Ortuño J. Has androgen therapy a role in the erythropoietin era? Nephrol Dial Transplant 1994; 9: 1027.
   Google Scholar
• Babaian RJ, Miyashita H, Evans RB, Ramirez EI. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: Relationship to gland volume and age. J Urol 1992; 147: 837–840.
   PubMed Web of Science ®Google Scholar
• Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29–33.
   PubMed Web of Science ®Google Scholar
• Bardin CW, Swerdloff RS, Santen RJ. Androgens: Risks and benefits. J Clin Endocrinol Metab 1991; 73: 4–7.
   PubMed Web of Science ®Google Scholar
• Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. Clin Nephrol 1992; 37: 264–267.
   PubMed Web of Science ®Google Scholar
• Brawer MK, Chetner MP, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147: 841–845.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–1161.
   PubMed Web of Science ®Google Scholar
• Cattran DC, Fenton SSA, Wilson DR, Oreopoulos D, Shimizu A, Richardson RM. A controlled trial of nandrolone decanoate in the treatment of uremic anemia. Kidney Int 1977; 12: 430–437.
   PubMed Web of Science ®Google Scholar
• Coffey DS. Physiological control of prostatic growth. In Prostate Cancer, an overview. UICC Workshop on Prostatic Cancer, 1978. Technical Report Series, Vol 48, Geneve, International Union Against Cancer, 1979: 4–23.
   Google Scholar
• Drago JR, Nesbitt JA, Badalement RA, et al. Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Urology 1989; 34: 187–192.
   PubMed Web of Science ®Google Scholar
• Gittes RF. Prostate-specific antigen. N Engl J Med 1987; 317: 954–955.
   PubMed Web of Science ®Google Scholar
• Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324: 236–245.
   PubMed Web of Science ®Google Scholar
• Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327: 1185–1191.
   PubMed Web of Science ®Google Scholar
• De Gowin RL, Lavender AR, Froland M, Charleston D, Gottschalk A. Erythropoiesis and erythropoietin in patients with chronic renal failure treated with hemodialysis and testosterone. Ann Intern Med 1970; 72: 913–918.
   PubMedGoogle Scholar
• von Hartitzsch B, Kerr DNS, Morley G, Marks B. Androgens in the anaemia of chronic renal failure. Nephron 1977; 18: 13–20.
   PubMed Web of Science ®Google Scholar
• Holund B. Latent prostatic cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980; 14: 29–35.
   PubMed Web of Science ®Google Scholar
• Hudson MA, Bahson RR, Catalona WJ. Clinical use of prostatic specific antigen in patients with prostate cancer. J Urol 1989; 142: 1011–1017.
   PubMed Web of Science ®Google Scholar
• Kuriyama M, Wang MC, Lee CL, et al. Multiple marker evaluation in human prostate cancer with the use of tissue-specific antigens. JNCI 1982; 68: 99–105.
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846–852.
   PubMed Web of Science ®Google Scholar
• Mirahmadi MK, Vaziri ND, Gorman JT. Controlled evaluation of hemodialysis patients on nandrolone decanoate (ND) vs testosterone enanthate (TE). Trans Am Soc Artif Intern Organs 1979; 25: 449–453.
   PubMedGoogle Scholar
• Monath JR, Pittaway DE, Burkart JM, Russell GB, Freedman BI, Assimos DG. Effects of hemodialysis on prostate-specific antigen. Urology 1993; 42: 398–400.
   PubMed Web of Science ®Google Scholar
• Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977; 37: 1929–1933.
   PubMed Web of Science ®Google Scholar
• Pascual J, Teruel JL, Marcen R, Liaño F, Ortuño J. Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 1992; 15: 393–396.
   PubMed Web of Science ®Google Scholar
• Port FK, Schwartz AG, Ragheb N, Hawthorne VM. The incidence of neoplasms in dialysis patients: A population-based, age-controlled analysis. Kidney Int 1987; 31: 242.
   Web of Science ®Google Scholar
• Richardson JRJr, Weinstein MB. Erythropoietic response of dialyzed patients to testosterone administration. Ann Intern Med 1970; 73: 403–407.
   PubMed Web of Science ®Google Scholar
• Sasagawa I, Nakada T, Hashimoto T, et al. Serum prostatic acid phosphatase, gammaseminoprotein and prostatic specific antigen in hemodialysis patients. Urol Int 1992; 48: 181–183.
   PubMed Web of Science ®Google Scholar
• Shahidi NT. Androgens and erythropoiesis. Engl J Med 1973; 298: 72–80.
   Google Scholar
• Stamey TA, Kabalin JN. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141. 1070–1075.
   PubMed Web of Science ®Google Scholar
• Teruel JL, Quereda C, Martin E, Orofino L, Liaño F, Ortuño J. Tratamiento de la anemia no ferropénica en hemodiálisis mediante anabolizantes. Nefrología 1983; III: 273–278.
   Google Scholar
• Walsh PC. Benign prostatic hyperplasia. In: Harrison JH, Gittes RF, Perlmutter AD, Stamey TA, Walsh PC eds. Campbell's Urology, Philadelphia: WB Saunders Co, 1986, pp 1248–1305.
   Google Scholar